Silence Therapeutics PV Data: Binary Risk for SLN Stock

Silence Therapeutics faces a binary event in the second half of the year when the company reports phase 2 data for its lead candidate divesiran in polycythemia vera. The outcome will determine the near-term trajectory for SLN stock.

The company has no marketed products. Divesiran is the furthest along in the pipeline, an RNAi therapy designed to reduce red blood cell production. The phase 2 trial is evaluating the drug in patients who require regular phlebotomy. Silence Therapeutics has guided for data in the second half.

Positive results showing a reduction in phlebotomy frequency and improved hematocrit control would support the drug's profile and potentially open a path to registration, the company has said. Negative or mixed results would raise questions about the mechanism and the broader RNAi platform, similar to setbacks seen in other RNAi programs. The company is scheduled to present at a medical conference later this year, though no exact date has been set.